Anvisa says biosimilar switching can be done safely under approved conditions, aligning Brazil with international regulators while stressing monitoring, traceability and safeguards against unplanned changes.
Anvisa says biosimilar switching can be done safely under approved conditions, aligning Brazil with international regulators while stressing monitoring, traceability and safeguards against unplanned changes.